Trial Information
Summary: A Phase I Study of Vinblastine in Combination with Carboplatin for Children with Newly Diagnosed and Recurrent Low Grade Gliomas
What is the purpose of this study?
The goals of this research study are:
- To find the highest safe dose of vinblastine that can be given
in combination with carboplatin without causing severe side
effects
- To learn what kind of side effects the combination of
vinblastine and carboplatin can cause
- To learn more about what kind of changes can be seen in the
tumor on MRI scans after giving the combination of vinblastine and
carboplatin
- To determine whether the combination of vinblastine and
carboplatin is a beneficial treatment for the patient’s
tumor
Who will be included in this study?
Patients with low-grade gliomas and who are = 21 years old are
eligible to participate in this clinical trial.
What is involved?
Patients receive carboplatin and vincristine treatment every 6
weeks. Patients may be in the study for a little over 12 months if
the patient’s tumor does not grow.
Before the Study begins
Patients will need to have the following exams, tests, or
procedures to find out if the patient can be in the study. These
exams, tests, or procedures are part of regular cancer care and may
be done even if patients do not join the study. If some test have
been performed recently, they may not need to be repeated. This
will be up to the study doctor.
- A medical history and vital signs (blood pressure, pulse, and
temperature)
- Physical exam
- Blood tests
- Pregnancy test for females of childbearing age
- MRI Scans (a MRI uses magnetic waves to make pictures of the
brain, so we can see the tumor)
During the Study
Patients will also be given the following tests and procedures
during the study. These test and procedures are part of regular
low-grade glioma care:
- Physical exam
- Blood tests
- MRI scans
- Eye exams if you have a tumor involving the visual
pathway
What are the benefits?
There may be no direct benefit for participants who agree to take
part in this research study. The potential benefit of the treatment
with vinblastine in combination with carboplatin is that it may
cause the patient’s tumor to stop growing or to shrink for a period
of time. It may lessen the symptoms that are caused by this tumor.
Because there is not much information about the effect of
vinblastine when given together with carboplatin, we do not know if
the patient will benefit from taking part in this study.
Information learned from this study may help future patients with
cancer. The disease may continue to become worse despite taking
these cancer drugs.
Will I get all the facts about the study?
Parents interested in having their child participate will be given
a consent form that thoroughly explains all of the details of the
study. It goes over all of the procedures, the risks, the benefits,
the compensation, who to contact with questions or concerns and
more. A member of the study staff will review the consent form with
the patient and will be sure that all of the patient’s questions
are answered. Study procedures will not begin until a
parent/guardian or adult subject has signed this form and, if of
age, the child has given at minimum his/her verbal agreement.
What are the risks?
A detailed list of side effects can be provided to those patients
interested in knowing more about the study.
For more information,
|
Contact:
Rebecca Turner, MS, CCRP
Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
Division of Hematology/Oncology
3333 Burnet Ave
Cincinnati, OH 45229-3039
Telephone: 513-636-0215
Email:
|
|

If you would like to learn more about participating in this study, please send an e-mail message using the form below.
Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.
This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.
Trial listings updated: June 1, 2008 at 6:30:07 AM